# Metformin Drug Interactions

## Drug Overview
- **Generic Name:** Metformin
- **Drug Class:** Biguanide
- **Primary Use:** Type 2 Diabetes Mellitus (first-line therapy)
- **Mechanism:** Decreases hepatic glucose production, decreases intestinal glucose absorption, improves insulin sensitivity
- **FDA Approval:** 1994

---

## Major Drug-Drug Interactions (Severity: HIGH - Avoid Combinations)

### 1. Iodinated Contrast Media
- **Interacting Drugs:** Diatrizoate, Iodixanol, Iohexol, Iopamidol, Iopromide, Iothalamate, Ioversol, Ioxaglate, Ioxilan, Iodamide, Iodipamide, Iomeprol, Metrizamide
- **Interaction Type:** Increased risk of lactic acidosis
- **Mechanism:** Contrast media can cause acute kidney injury, leading to metformin accumulation
- **Clinical Effect:** Life-threatening lactic acidosis
- **Management:** Discontinue metformin at time of or before procedure; withhold for 48 hours after; restart only after renal function confirmed normal
- **Source:** FDA Prescribing Information; Drugs.com Drug Interactions Database

### 2. Carbonic Anhydrase Inhibitors
- **Interacting Drugs:** Acetazolamide, Dichlorphenamide, Methazolamide, Topiramate, Zonisamide
- **Interaction Type:** Increased risk of lactic acidosis
- **Mechanism:** These drugs reduce renal bicarbonate excretion, interfering with acid-base balance
- **Clinical Effect:** Metabolic acidosis, increased lactic acidosis risk
- **Management:** Consider benefits vs risks; more frequent monitoring required
- **Source:** FDA Prescribing Information (Riomet ER Label 2019); DailyMed

### 3. Dolutegravir
- **Interacting Drug:** Dolutegravir (HIV integrase inhibitor)
- **Interaction Type:** Pharmacokinetic - increased metformin levels
- **Mechanism:** Dolutegravir inhibits renal tubular secretion of metformin via OCT2 transporter
- **Clinical Effect:** 66-145% increase in metformin AUC; increased risk of adverse effects
- **Management:** Consider dose adjustment of metformin; monitor closely
- **Source:** FDA Prescribing Information; DailyMed

### 4. Ranolazine
- **Interacting Drug:** Ranolazine (antianginal)
- **Interaction Type:** Pharmacokinetic - increased metformin accumulation
- **Mechanism:** Inhibits renal tubular secretion of metformin
- **Clinical Effect:** Increased metformin plasma concentrations
- **Management:** Consider benefits and risks; may need dose adjustment
- **Source:** FDA Prescribing Information; Drugs.com

### 5. Ethanol (Alcohol)
- **Interacting Substance:** Ethanol
- **Interaction Type:** Major drug-food interaction
- **Mechanism:** Alcohol potentiates effect on lactate metabolism; impairs gluconeogenesis
- **Clinical Effect:** Increased risk of lactic acidosis; hypoglycemia
- **Management:** Avoid excessive alcohol intake; contraindicated with uncontrolled diabetes
- **Source:** FDA Prescribing Information; Drugs.com

### 6. Levoketoconazole
- **Interacting Drug:** Levoketoconazole
- **Interaction Type:** Increased metformin accumulation
- **Mechanism:** Reduces metformin clearance
- **Clinical Effect:** Elevated metformin levels, increased lactic acidosis risk
- **Management:** Consider alternative; close monitoring required
- **Source:** Drugs.com Drug Interactions Database

### 7. Gatifloxacin
- **Interacting Drug:** Gatifloxacin (fluoroquinolone antibiotic)
- **Interaction Type:** Unpredictable glucose effects
- **Mechanism:** Gatifloxacin causes severe, unpredictable blood glucose disturbances
- **Clinical Effect:** Both severe hypoglycemia and hyperglycemia reported
- **Management:** Avoid combination; use alternative antibiotic
- **Source:** FDA Prescribing Information; Drugs.com

---

## Moderate Drug-Drug Interactions (Severity: MODERATE - Use with Caution)

### Drugs That INCREASE Hypoglycemia Risk (Pharmacodynamic Synergism)

#### Insulin and Insulin Secretagogues
- **Interacting Drugs:** All insulins (regular, glargine, lispro, aspart, detemir, degludec), Glipizide, Glimepiride, Glyburide, Repaglinide, Nateglinide
- **Interaction Type:** Additive blood glucose lowering
- **Clinical Effect:** Increased hypoglycemia risk
- **Management:** May need to reduce insulin/secretagogue dose when adding metformin
- **Source:** FDA Prescribing Information; Drugs.com

#### ACE Inhibitors
- **Interacting Drugs:** Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril
- **Interaction Type:** Enhanced glucose-lowering effect
- **Mechanism:** ACE inhibitors may improve insulin sensitivity
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor blood glucose; adjust doses as needed
- **Source:** Medscape Drug Interactions; FDA Prescribing Information

#### SGLT2 Inhibitors
- **Interacting Drugs:** Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced efficacy; increased hypoglycemia risk when combined with insulin
- **Management:** Commonly prescribed together; monitor glucose levels
- **Source:** FDA Prescribing Information; Drugs.com

#### GLP-1 Receptor Agonists
- **Interacting Drugs:** Semaglutide (Ozempic), Dulaglutide (Trulicity), Liraglutide, Exenatide
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced glycemic control; possible hypoglycemia
- **Management:** Commonly prescribed together; safe combination
- **Source:** FDA Prescribing Information; Clinical Practice Guidelines

#### Salicylates
- **Interacting Drugs:** Aspirin (high-dose), Salsalate
- **Interaction Type:** Enhanced glucose lowering
- **Mechanism:** Salicylates have intrinsic glucose-lowering properties
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor blood glucose with high-dose salicylate therapy
- **Source:** Drugs.com; FDA Prescribing Information

### Drugs That DECREASE Metformin Efficacy (May Cause Hyperglycemia)

#### Corticosteroids
- **Interacting Drugs:** Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Cortisone, Betamethasone, Fludrocortisone, Deflazacort, Budesonide
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Corticosteroids increase hepatic gluconeogenesis and cause insulin resistance
- **Clinical Effect:** Loss of glycemic control; hyperglycemia
- **Management:** Monitor glucose closely; may need to increase metformin or add other agents
- **Source:** FDA Prescribing Information; Drugs.com

#### Thiazide and Loop Diuretics
- **Interacting Drugs:** Hydrochlorothiazide, Furosemide, Bumetanide, Torsemide, Chlorothiazide, Indapamide, Metolazone, Ethacrynic acid
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Diuretics can cause hyperglycemia and hypokalemia
- **Clinical Effect:** Decreased glucose control
- **Management:** Monitor blood glucose; adjust therapy as needed
- **Source:** FDA Prescribing Information; Drugs.com

#### Atypical Antipsychotics
- **Interacting Drugs:** Olanzapine, Clozapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, Paliperidone, Lurasidone, Asenapine
- **Interaction Type:** Metabolic effects
- **Mechanism:** Atypical antipsychotics cause weight gain and insulin resistance
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor glucose closely; lifestyle modifications important
- **Source:** FDA Prescribing Information; NCBI Bookshelf

#### Thyroid Hormones
- **Interacting Drugs:** Levothyroxine, Liothyronine, Thyroid desiccated
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Thyroid hormones increase glucose absorption and hepatic glucose output
- **Clinical Effect:** May worsen glycemic control in hyperthyroid states
- **Management:** Monitor glucose when starting or adjusting thyroid medications
- **Source:** FDA Prescribing Information; Drugs.com

#### Sympathomimetics
- **Interacting Drugs:** Epinephrine, Norepinephrine, Pseudoephedrine, Phenylephrine, Albuterol, Formoterol, Salmeterol, Terbutaline
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Beta-agonists stimulate glycogenolysis and gluconeogenesis
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor blood glucose; may need temporary dose adjustment
- **Source:** FDA Prescribing Information; Drugs.com

#### Estrogens and Oral Contraceptives
- **Interacting Drugs:** Ethinyl estradiol, Conjugated estrogens, Estradiol, Combined oral contraceptives
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Estrogens may impair glucose tolerance
- **Clinical Effect:** Possible decrease in glycemic control
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information; Drugs.com

#### Phenytoin
- **Interacting Drug:** Phenytoin (anticonvulsant)
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Phenytoin inhibits insulin secretion
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor glucose closely
- **Source:** FDA Prescribing Information; Drugs.com

#### Nicotinic Acid (Niacin)
- **Interacting Drug:** Niacin/Nicotinic acid
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Niacin can impair glucose tolerance
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor glucose when initiating niacin therapy
- **Source:** FDA Prescribing Information; Drugs.com

#### Calcium Channel Blockers
- **Interacting Drugs:** Nifedipine, Verapamil, Diltiazem, Amlodipine
- **Interaction Type:** Mixed effects
- **Mechanism:** May affect insulin secretion; nifedipine increases metformin absorption
- **Clinical Effect:** Variable glycemic effects
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information (Nifedipine interaction noted)

### Drugs That Affect Metformin Pharmacokinetics

#### Cationic Drugs (Renal Competition)
- **Interacting Drugs:** Cimetidine, Vancomycin, Trimethoprim, Digoxin, Procainamide, Quinidine, Morphine, Amiloride, Triamterene
- **Interaction Type:** Pharmacokinetic competition
- **Mechanism:** Compete for renal tubular secretion
- **Clinical Effect:** Increased metformin plasma levels
- **Management:** Use with caution; monitor for metformin side effects
- **Source:** FDA Prescribing Information; DailyMed

---

## Minor Drug-Drug Interactions (Severity: LOW - Minimal Risk)

### Alpha-Lipoic Acid
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** May enhance metformin efficacy
- **Management:** Monitor blood glucose
- **Source:** Drugs.com

### Acarbose
- **Interaction Type:** Additive effect
- **Clinical Effect:** Possible enhanced glucose control
- **Management:** Generally safe combination
- **Source:** Drugs.com

### Garlic
- **Interaction Type:** Possible additive glucose lowering
- **Clinical Effect:** Minimal clinical significance
- **Management:** No specific action needed
- **Source:** Drugs.com

---

## Drug-Food Interactions

### Alcohol
- **Severity:** Major
- **Mechanism:** Potentiates metformin's effect on lactate metabolism; inhibits gluconeogenesis
- **Clinical Effect:** Increased risk of lactic acidosis; hypoglycemia
- **Recommendation:** Avoid excessive alcohol; avoid if diabetes poorly controlled
- **Source:** FDA Prescribing Information; Drugs.com

### Grapefruit Juice
- **Severity:** None reported
- **Note:** No significant interaction documented
- **Source:** FDA Prescribing Information

### High-Fiber Meals
- **Severity:** Minor
- **Mechanism:** May slightly reduce metformin absorption
- **Clinical Effect:** Minimal clinical significance
- **Recommendation:** Take with meals to reduce GI side effects
- **Source:** Clinical pharmacology literature

---

## Disease Interactions

### 1. Lactic Acidosis Risk (Major)
- **Conditions:** Hepatic impairment, renal dysfunction, acute/decompensated heart failure, respiratory failure, sepsis, dehydration
- **Risk:** Metformin accumulation leading to fatal lactic acidosis
- **Management:** Contraindicated in severe hepatic/renal impairment; discontinue if acute illness occurs
- **Source:** FDA Black Box Warning; Prescribing Information

### 2. Renal Dysfunction (Major)
- **Conditions:** eGFR <30 mL/min/1.73mÂ²
- **Risk:** Metformin accumulation
- **Management:** Contraindicated if eGFR <30; assess risk/benefit if eGFR 30-45
- **Source:** FDA Prescribing Information (2016 revision)

### 3. Liver Disease (Major)
- **Conditions:** Hepatic impairment
- **Risk:** Impaired lactate clearance
- **Management:** Avoid in patients with clinical/laboratory evidence of hepatic disease
- **Source:** FDA Prescribing Information

### 4. Hypoglycemia (Moderate)
- **Risk:** When combined with insulin or insulin secretagogues
- **Management:** May need to reduce doses of other antidiabetic agents
- **Source:** FDA Prescribing Information

### 5. Vitamin B12 Deficiency (Moderate)
- **Risk:** Long-term metformin use associated with B12 malabsorption
- **Management:** Monitor B12 levels at 2-3 year intervals; supplement if deficient
- **Source:** FDA Prescribing Information; NCBI Bookshelf

---

## Summary Statistics
- **Total Known Drug Interactions:** 393
- **Major Interactions:** 25
- **Moderate Interactions:** 352
- **Minor Interactions:** 16
- **Disease Interactions:** 5
- **Food/Alcohol Interactions:** 1

---

## Clinical Recommendations for Safe Use

1. **Before Starting Metformin:**
   - Assess renal function (eGFR)
   - Evaluate hepatic function
   - Review complete medication list for interactions
   - Screen for alcohol use

2. **During Therapy:**
   - Monitor renal function at least annually
   - Check B12 levels every 2-3 years
   - Temporarily discontinue before contrast procedures
   - Hold during acute illness causing dehydration

3. **Patient Education:**
   - Recognize symptoms of lactic acidosis (malaise, myalgias, respiratory distress, abdominal pain)
   - Avoid excessive alcohol
   - Inform healthcare providers about metformin before procedures
   - Report any acute illness

---

## References
1. FDA Prescribing Information - Metformin Hydrochloride
2. Drugs.com Drug Interactions Database (https://www.drugs.com/drug-interactions/metformin.html)
3. DailyMed - U.S. National Library of Medicine
4. NCBI Bookshelf - Metformin StatPearls (August 2023)
5. Medscape Drug Interactions Reference
6. American Diabetes Association Standards of Care
7. FDA Drug Safety Communication on Metformin and Renal Function
